Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, comments on the role of autologous hematopoietic stem cell transplantation (autoHSCT) in the treatment of young and fit patients with multiple myeloma in the era of novel immunotherapeutic agents. Prof. Mohty argues that the Phase III DETERMINATION study (NCT01208662) confirmed the role of autoHSCT as a standard of care in this patient population. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
